527.77USD-1.62%Mkt Cap: —P/E: —1d ago
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directe…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value11.84B $
Revenue (TTM)1.28B $
Gross Profit1.17B $
Net Income (TTM)-325.10M $
Revenue/Share56.15 USD
Last Price527.77 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees915
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS5588681057
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-36.88
EV/Revenue9.22
P/S—
P/B23.44
EPS (TTM)-14.65
EPS (Forward)—
52W Range
514.0049% of range542.33
52W High542.33 USD
52W Low514.00 USD
Profitability
Gross Margin91.48%
Oper. Margin-15.46%
EBITDA Margin-25.01%
Profit Margin-25.32%
ROE-53.31%
ROA-17.84%
Growth
Revenue Growth71.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-197.72M $
CapEx (TTM)—
FCF Margin-6.27%
FCF Yield—
Net Debt-491.00M $
Net Debt/EBITDA1.53
Balance Sheet
Debt/Equity66.40
Current Ratio3.21
Quick Ratio2.75
Book Value/Sh22.68 USD
Cash/Share36.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.15.39M
Float13.73M
Insiders5.87%
Institutions104.43%
Technical
SMA 50231.01 (+128.5%)
SMA 200217.37 (+142.8%)
Beta-1.00
S&P 52W Chg20.80%
Avg Vol (30d)15
Avg Vol (10d)347
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—